Pharming Group N.V. Statistics
Share Statistics
Pharming Group N.V. has 517.37M shares outstanding. The number of shares has increased by 2.91% in one year.
| Shares Outstanding | 517.37M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.73% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 381.64M |
| Failed to Deliver (FTD) Shares | 52 |
| FTD / Avg. Volume | 0.72% |
Short Selling Information
The latest short interest is 9.62K, so 0.01% of the outstanding shares have been sold short.
| Short Interest | 9.62K |
| Short % of Shares Out | 0.01% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 1.32 |
Valuation Ratios
The PE ratio is -88.51 and the forward PE ratio is null.
| PE Ratio | -88.51 |
| Forward PE | null |
| PS Ratio | 3.81 |
| Forward PS | 1.5 |
| PB Ratio | 4.27 |
| P/FCF Ratio | -49.75 |
| PEG Ratio | n/a |
Enterprise Valuation
Pharming Group N.V. has an Enterprise Value (EV) of 921.75M.
| EV / Earnings | -87.39 |
| EV / Sales | 3.76 |
| EV / EBITDA | 93.32 |
| EV / EBIT | -188.9 |
| EV / FCF | -49.12 |
Financial Position
The company has a current ratio of 4.06, with a Debt / Equity ratio of 0.63.
| Current Ratio | 4.06 |
| Quick Ratio | 3.33 |
| Debt / Equity | 0.63 |
| Total Debt / Capitalization | 38.75 |
| Cash Flow / Debt | -0.12 |
| Interest Coverage | -0.82 |
Financial Efficiency
Return on equity (ROE) is -0.05% and return on capital (ROIC) is -1.1%.
| Return on Equity (ROE) | -0.05% |
| Return on Assets (ROA) | -0.02% |
| Return on Capital (ROIC) | -1.1% |
| Revenue Per Employee | 642.19K |
| Profits Per Employee | -27.61K |
| Employee Count | 382 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 0.44 |
Taxes
| Income Tax | -1.46M |
| Effective Tax Rate | 0.12 |
Stock Price Statistics
The stock price has increased by -23.9% in the last 52 weeks. The beta is 0.81, so Pharming Group N.V.'s price volatility has been higher than the market average.
| Beta | 0.81 |
| 52-Week Price Change | -23.9% |
| 50-Day Moving Average | 8.28 |
| 200-Day Moving Average | 8.85 |
| Relative Strength Index (RSI) | 68.97 |
| Average Volume (20 Days) | 7.18K |
Income Statement
In the last 12 months, Pharming Group N.V. had revenue of $245.32M and earned -$10.55M in profits. Earnings per share was $-0.01.
| Revenue | 245.32M |
| Gross Profit | 220.10M |
| Operating Income | -4.88M |
| Net Income | -10.55M |
| EBITDA | 9.88M |
| EBIT | -4.88M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has $61.74M in cash and $171.54M in debt, giving a net cash position of -$109.80M.
| Cash & Cash Equivalents | 61.74M |
| Total Debt | 171.54M |
| Net Cash | -109.80M |
| Retained Earnings | -265.26M |
| Total Assets | 425.51M |
| Working Capital | 202.35M |
Cash Flow
In the last 12 months, operating cash flow was -$17.30M and capital expenditures -$1.46M, giving a free cash flow of -$18.77M.
| Operating Cash Flow | -17.30M |
| Capital Expenditures | -1.46M |
| Free Cash Flow | -18.77M |
| FCF Per Share | -0.02 |
Margins
Gross margin is 89.72%, with operating and profit margins of -1.99% and -4.3%.
| Gross Margin | 89.72% |
| Operating Margin | -1.99% |
| Pretax Margin | -4.9% |
| Profit Margin | -4.3% |
| EBITDA Margin | 4.03% |
| EBIT Margin | -1.99% |
| FCF Margin | -7.65% |
Dividends & Yields
PHAR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.11% |
| FCF Yield | -4.04% |
Analyst Forecast
The average price target for PHAR is $30, which is 234.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $30 |
| Price Target Difference | 234.1% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 1.65 |
| Piotroski F-Score | 5 |